Neurodegenerative disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Neurodegenerative disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Donanemab in People With Early Symptomatic Alzheimer’s Disease https://clinicaltrials.eu/trial/a-study-of-donanemab-in-people-with-early-symptomatic-alzheimers-disease/ Wed, 29 Apr 2026 15:07:45 +0000 https://clinicaltrials.eu/trial/a-study-of-donanemab-in-people-with-early-symptomatic-alzheimers-disease/ This study is looking at Alzheimer’s disease in people who are in the early stages of the condition. Alzheimer’s disease is a brain disorder that gradually affects memory, thinking, and the ability to carry out daily activities. The study will test a medication called donanemab (also known by its code name LY3002813), which is an antibody designed to target a protein called amyloid beta that builds up in the brains of people with Alzheimer’s disease. Some participants will receive donanemab while others will receive placebo. The study will also use special imaging substances called florbetapir (code name LY3078786) and flortaucipir (code name LY3191748) that help doctors see protein deposits in the brain through scanning procedures. Sodium chloride will be used as part of the treatment process.

The purpose of this study is to see whether donanemab can slow down the worsening of symptoms compared to placebo in people with early symptomatic Alzheimer’s disease. The study will measure changes in memory, thinking abilities, and daily functioning over time to determine if the treatment is effective.

During the study, participants will receive the study medication through an infusion into a vein. The treatment will continue for a period of time while doctors monitor how well participants are doing with their memory and daily activities. Participants will need to have a study partner who knows them well and can provide information about any changes in their condition. The study will use brain scans to check for the presence of certain proteins that are associated with Alzheimer’s disease. These scans help doctors understand the extent of the disease and monitor any changes during the study.

]]> Study on the Effects of Dexmedetomidine on Brain Fluid Flow and Activity in Patients with Neurodegenerative Diseases, Delirium, or Acute Neurological Conditions https://clinicaltrials.eu/trial/study-on-the-effects-of-dexmedetomidine-on-brain-fluid-flow-and-activity-in-patients-with-neurodegenerative-diseases-delirium-or-acute-neurological-conditions/ Wed, 29 Apr 2026 15:05:47 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-dexmedetomidine-on-brain-fluid-flow-and-activity-in-patients-with-neurodegenerative-diseases-delirium-or-acute-neurological-conditions/ This clinical trial is focused on studying the effects of a medication called Dexmedetomidine on the brain. The diseases being studied include neurodegenerative disease, delirium, and acute neurological disease. The purpose of the study is to understand how this medication influences brain functions such as blood flow and the movement of cerebrospinal fluid, which is a clear liquid surrounding the brain and spinal cord. The study will use a technique called functional Magnetic Resonance Imaging (MRI) to observe these effects.

Participants in the study will receive Dexmedetomidine through an intravenous infusion, which means it will be administered directly into a vein. The study will observe changes in brain activity and blood flow while participants are awake and under different levels of sedation caused by the medication. The study will also use electroencephalography (EEG), a method to record electrical activity of the brain, to gather more information about how the brain functions during these different states.

The study aims to gather data on how Dexmedetomidine affects brain signals and other bodily functions, such as blood pressure and heart rate. This information will help researchers understand the potential benefits and effects of the medication on brain health, particularly in relation to the diseases being studied. The study will also look at how the medication affects various biomarkers, which are substances in the body that can indicate how well the body is functioning or responding to treatment.

]]> Study on the Accuracy of Tau PET ([18F]RO6958948) and Vizamyl (Flutemetamol 18F) in Diagnosing Mild Cognitive Symptoms and Risk of Alzheimer’s Disease https://clinicaltrials.eu/trial/study-on-the-accuracy-of-tau-pet-18fro6958948-and-vizamyl-flutemetamol-18f-in-diagnosing-mild-cognitive-symptoms-and-risk-of-alzheimers-disease/ Wed, 29 Apr 2026 15:05:45 +0000 https://clinicaltrials.eu/trial/study-on-the-accuracy-of-tau-pet-18fro6958948-and-vizamyl-flutemetamol-18f-in-diagnosing-mild-cognitive-symptoms-and-risk-of-alzheimers-disease/ The study focuses on understanding and improving the diagnosis of certain brain disorders known as neurodegenerative disorders. These include conditions like Alzheimer’s disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration, and mild cognitive impairment. The study uses two special substances, Vizamyl and [18F]RO6958948, which are injected into the body to help doctors see changes in the brain using a type of scan called PET (Positron Emission Tomography).

The purpose of the study is to see how well these substances can help identify people who are at risk of developing dementia, a condition that affects memory and thinking. Participants in the study will receive an injection of either Vizamyl or [18F]RO6958948. These substances help highlight areas in the brain that may be affected by the disorders. The study will compare the brain scans of people with these disorders to those of healthy individuals to better understand the differences.

Throughout the study, participants will undergo various tests, including brain scans and cognitive assessments, to monitor their brain health and cognitive function. The study aims to gather information over time to see how these disorders progress and how the substances used in the study can aid in early detection and diagnosis. This research hopes to provide valuable insights into the early stages of these disorders and improve the way they are diagnosed and understood.

]]> Study of Latozinemab for Patients with Neurodegenerative Diseases Who Previously Participated in a Latozinemab Study https://clinicaltrials.eu/trial/study-of-latozinemab-for-patients-with-neurodegenerative-diseases-who-previously-participated-in-a-latozinemab-study/ Wed, 29 Apr 2026 15:00:30 +0000 https://clinicaltrials.eu/trial/study-of-latozinemab-for-patients-with-neurodegenerative-diseases-who-previously-participated-in-a-latozinemab-study/ This clinical trial is focused on studying neurodegenerative diseases, which are conditions that involve the gradual loss of nerve cells in the brain. The treatment being investigated is called latozinemab, a solution given through an intravenous infusion, meaning it is administered directly into the bloodstream. The purpose of this study is to provide continued access to latozinemab for participants who have previously taken part in a study involving this treatment.

Participants in this study will receive latozinemab over a period of time, with the maximum treatment period being 39 weeks. The study will monitor the number of participants receiving the treatment and the duration of their treatment. Additionally, the study will observe any adverse events, which are unwanted effects that may occur during the treatment, and the development of any antibodies against latozinemab, which are proteins the body might produce in response to the treatment.

The study will also assess the participants’ condition using specific scales every three months. These scales help to evaluate the severity of the disease and any changes in the participants’ condition over time. The study aims to gather information on the safety and effects of latozinemab in individuals with neurodegenerative diseases, ensuring that those who have previously benefited from the treatment can continue to receive it.

]]>